Activity of vancomycin, linezolid, and daptomycin against staphylococci and enterococci isolated in 5 Greek hospitals during a 5-year period (2008-2012).
The tendency of vancomycin, linezolid, and daptomycin MICs was investigated among 6920 staphylococci and enterococci during a 5-year period. Antimicrobial consumption was determined. Decrease of vancomycin MIC was detected associated with reduction in consumption. Linezolid and daptomycin remained active. An upward trend of linezolid MIC for methicillin-resistant staphylococci was observed.
Division of Infectious Diseases, School of Medicine, University of Patras, Patras, Greece.
Matthaios
M
Papadimitriou-Olivgeris
Department of Microbiology, School of Medicine, University of Patras, Patras, Greece.
Fevronia
F
Kolonitsiou
Department of Microbiology, Attikon University Hospital, Athens, Greece.
Loukia
L
Zerva
Department of Microbiology, 'P&A Kyriakou' Children's Hospital, Athens, Greece.
Evangelia
E
Lebessi
Department of Microbiology, "Asclepeion" General Hospital, Athens, Greece.
Chryssa
C
Koutsia
Department of Microbiology, School of Medicine, University of Patras, Patras, Greece.
Eleanna
E
Drougka
Department of Microbiology, University General Hospital of Larissa, Larissa, Greece.
Styliani
S
Sarrou
Department of Microbiology, School of Medicine, University of Patras, Patras, Greece.
Nikolaos
N
Giormezis
Department of Microbiology, Attikon University Hospital, Athens, Greece.
Sofia
S
Vourli
Department of Microbiology, 'P&A Kyriakou' Children's Hospital, Athens, Greece.
Anastassios
A
Doudoulakakis
Department of Microbiology, "Asclepeion" General Hospital, Athens, Greece.
Christos
C
Konsolakis
Division of Infectious Diseases, School of Medicine, University of Patras, Patras, Greece.
Markos
M
Marangos
Department of Microbiology, School of Medicine, University of Patras, Patras, Greece.
Evangelos D
ED
Anastassiou
Department of Microbiology, University General Hospital of Larissa, Larissa, Greece.
Efthimia
E
Petinaki
Department of Microbiology, School of Medicine, University of Patras, Patras, Greece. Electronic address: spiliopl@upatras.gr.
Iris
I
Spiliopoulou
D000900:Anti-Bacterial Agents / Q000494:pharmacology*; D017576:Daptomycin / Q000494:pharmacology*; D004363:Drug Utilization; D016983:Enterococcus / Q000187:drug effects* / Q000302:isolation & purification; D016908:Gram-Positive Bacterial Infections / Q000382:microbiology*; D006115:Greece; D006761:Hospitals; D006801:Humans; D000069349:Linezolid / Q000494:pharmacology*; D008826:Microbial Sensitivity Tests; D013210:Staphylococcus / Q000187:drug effects* / Q000302:isolation & purification; D014640:Vancomycin / Q000494:pharmacology*
D000900:Anti-Bacterial Agents; D014640:Vancomycin; D000069349:Linezolid; D017576:Daptomycin
Creep; MIC; Methicillin-resistant Staphylococcus aureus (MRSA); Vancomycin-resistant Enterococcus (VRE)